Uncategorized
NICE recommends Ozurdex for noninfectious posterior uveitis
The National Institute for Health and Care Excellence in the United Kingdom has issued a final appraisal determination recommending Ozurdex for the treatment of noninfectious posterior uveitis, according to an Allergan press release. If confirmed as final guidance, the final appraisal determination would allow Ozurdex (dexamethasone 0.7 mg intravitreal implant) to be a fully funded treatment option for patients with noninfectious uveitis in the posterior segment. It is already funded for posterior segment uveitis in some parts of the U.K., the release said.